Compare CLMB & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | MRVI |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.5M | 472.8M |
| IPO Year | 1996 | 2020 |
| Metric | CLMB | MRVI |
|---|---|---|
| Price | $118.86 | $3.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $136.00 | $4.57 |
| AVG Volume (30 Days) | 42.9K | ★ 938.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | ★ 49.26 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | ★ $465,607,000.00 | $259,185,000.00 |
| Revenue This Year | $37.27 | N/A |
| Revenue Next Year | $4.75 | $10.00 |
| P/E Ratio | $37.86 | ★ N/A |
| Revenue Growth | ★ 32.27 | N/A |
| 52 Week Low | $88.90 | $1.67 |
| 52 Week High | $145.00 | $4.22 |
| Indicator | CLMB | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 38.23 |
| Support Level | $115.31 | $2.88 |
| Resistance Level | $119.27 | $3.13 |
| Average True Range (ATR) | 3.86 | 0.15 |
| MACD | -0.48 | -0.01 |
| Stochastic Oscillator | 39.51 | 28.00 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.